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SUMMARY
Background. Glucose transporter type 1 deficiency syndrome (GLUT1-DS) is a treatable metabolic dis-
order caused by mutation in the SLC2A1 gene. The functional deficiency of the GLUT1 protein leads to 
impaired glucose transport into the brain, resulting in a spectrum of neurological phenotypes. The most 
severe classic phenotype comprises infantile-onset epileptic encephalopathy associated with delayed 
development, acquired microcephaly, motor coordination disturbances, and spasticity. The less severe 
clinical features, such as paroxysmal exercise-induced dystonia with or without epileptic seizures, are also 
observed.
Aim. Hypothesis, that one possible treatment option entails intrathecal injection of glucose.
Material and Methods. We describe a woman, who was diagnosed as having epilepsy and treated for 
years with different antiepileptic drugs with no clinical effect. She had only two generalized tonic clonic 
seizures in her life. The patient suffered from increasing frequency of the paroxysmal involuntary move-
ments of lower limbs, leading to gait disturbances and falls, which were misdiagnosed as epileptic sei-
zures. The jerks of the head and limbs were observed from the first months of her life. The symptoms were 
provoked by stress and exertion. Additionally, mild intellectual disability was noted during her growth.
Results. Glucose concentrations in cerebrospinal fluid were low. The SLC2A1 gene analysis resulted in 
the identification of a heterozygous missense mutation p.Arg333Trp. identification. The diagnosis of 
GLUT1-DS was confirmed.
Conclusion. Delayed diagnosis resulted in many problems with the acceptance of the ketogenic diet, 
which is considered the treatment of choice in GLUT1 deficiency syndromes. To our knowledge, this is the 
first case report of GLUT1-DS diagnosis occurring in adulthood and published in Poland.
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BACKGROUND
Glucose is the major carbon and energy source of nerve 
cells, supporting brain growth and neural excitation. 
The glucose transporter of capillary endothelial cells 
located at the blood brain barrier (BBB), facilitates the 
passive flux of glucose from blood to brain (Wong et 
al., 2007) and is also responsible for astrocyte glucose 
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transport. Glucose membrane transporters (GLUT) 
proteins are encoded by the SLC2 genes. They are mem-
bers of the major facilitator super family (MFS) which 
includes 14 different types of GLUT transporters in hu-
mans. Several rare congenital disorders, due to muta-
tions in various SLC2 genes have already been reported 
(Pearson et al., 2013). The SLC2A1 gene (MIM 138140) is 
the only one in which pathogenic variants are known to 
cause various glucose transporter type deficiency syn-
dromes: GLUT1-DS type1 (MIM 606777), GLUT1-DS 
type 2 (MIM612126), GLUT1-DS with pseudo hyper-
kalemia and hemolysis (MIM 608885) and idiopathic 
generalized epilepsy-12 (MIM 614847).
Haplodeficiency of GLUT1 due to heterozygous 
pathogenic variants in the SLC2A1 gene, mainly of an 
autosomal dominant inheritance, leads to chronic hy-
poglycorrachia (decreased cerebrospinal fluid glucose 
concentration) and neurological dysfunction, which 
constitute the defining features of the GLUT1-DS (Pas-
cual et al., 2007; De Vivo et al., 1991; Pascual et al., 2004). 
The GLUT1-DS usually presents as a classic form, with 
epileptic seizures (90%), but about 10% of patients are 
seizure-free. The phenotypic spectrum of GLUT1-DS 
is known to be a continuum between the classic pheno-
type and the dystonia 18, atypical childhood absence 
epilepsy, myoclonic astatic epilepsy, and paroxysmal 
non-epileptic findings (ataxia, choreoathetosis, dysto-
nia, and alternating hemiplegia).
The most severe GLUT1-DS type 1 is characterized 
by infantile-onset epileptic encephalopathy associated 
with delayed development, acquired microcephaly, mo-
tor incoordination and spasticity (Brockmann, 2017; De 
Giorgis, Veggiotti, 2013). The onset of seizures, is usual-
ly characterized by apneic episodes, staring spells, and 
episodic eye movements. They occur within the first 
4 months of life. Different types of seizures have been 
described – generalized tonic-clonic, absence, com-
plex partial, myoclonic (focal or generalized), drop sei-
zures, tonic (focal or generalized), simple partial, in-
fantile spasms. However, the generalized tonic-clon-
ic and absence seizures are the most common and of-
ten appear simultaneously (Brockmann, 2017). Other 
paroxysmal findings include intermittent ataxia, con-
fusion, lethargy, sleep disturbance, and headache. Var-
ying degrees of cognitive impairment can occur, rang-
ing from learning disabilities to severe intellectual dis-
ability. GLUT1-DS type 2 is a clinically variable disor-
der characterized primarily by paroxysmal exercise-
induced dyskinesia (DYT18) with onset in childhood. 
The dyskinesia involves transient abnormal involuntary 
movements, such as dystonia and choreoathetosis, in-
duced by exercise or exertion, and affects the exercised 
limbs. Some patients may also have epileptic seizures, 
most commonly childhood absence epilepsy. Mild in-
tellectual disability may also occur. In some patients 
a macrocytic hemolytic anemia has been described.
Under chronic brain glucose deprivation caused by 
GLUT1-DS, exogenous or endogenous substrates (i.e., 
ketone bodies and fatty acids) may serve as alterna-
tive fuels to maintain neural function. The ketogen-
ic diet is proved to be effective in controlling seizures 
and other paroxysmal events associated with GLUT1-
-DS (Friedman et al., 2006; Leary et al., 2003; Pérez-
Dueñas et al., 2009).
AIM
To discuss the possibility of different forms of GLUT1-
-DS therapy, especially in adult patients. We hypothe-
sized, that one possible treatment option may be by use 
of intrathecal glucose injection.
MATERIAL AND METHODS
A twenty year old woman was admitted to the neurolog-
ical department with a diagnoses of drug resistant epi-
lepsy. Her historical data were: the patient was born in 
at 39 week of pregnancy, birth weight 2900 g (10–25 c), 
length 53 cm (10–25 c), OFC 33cm (3–10 c) with an Ap-
gar Score 8. In the first week of her life she was treated 
with antibiotics because of otitis. Since that time, she 
was under neurological observation because of “uncon-
trolled” eye (nystagmus), head, limb movement, twist-
ing trunk, “stiffness” and fatigability of lower limbs. 
Subsequently, sudden “absence states”, “balance dis-
turbances” were observed, sometimes followed by col-
lapses and accompanied by increased muscles strains. 
The attacks resulted from even little effort. Tension of 
muscles was decreased in limbs. Her psychomotor de-
velopment was delayed. She started walking at the age 
of 2 y and 6 months. She began to speak at the age of 
3 years. At the age of four, the first generalized epilep-
tic seizure with prominent tonic phase, accompanied 
by salivation, oral automatisms and loss of conscious-
ness was observed. Epilepsy was diagnosed and valp-
roic acid (VPA) was administered 300 mg per day. The 
second and the last epileptic seizure was observed when 
she was six. She had been taking different antiepilep-
tic drugs for the next sixteen years, because of sudden 
involuntary movements and sudden collapses which 
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were diagnosed as epileptic seizures. In spite of many 
treatment modifications no clinical effect was noted. 
In the following years, the incidence of muscle fatiga-
bility, balance disturbances and anxiety lasting up to 
one hour, were often observed.
The patient was consulted by orthopedist (flat feet 
and knees valgus was found) and an otolaryngologist 
with no abnormalities in the examination. Psychologi-
cal tests revealed intellectual norm, however with pres-
ence of many slight abnormalities such as speech, caus-
al-effective thinking, graphomotor dexterity, sight per-
ception, apprehension accuracy, knowledge of norms, 
manual dexterity and optic-motor coordination dis-
turbances were noted.
Two sudden incidents of symptoms were diagnosed 
as transient ischemic attacks. During those attacks pa-
tient presented with speech difficulties defined as mo-
toric aphasia and pyramidal symptoms in right limbs, 
with involuntary movements of lower limbs and gait 
disturbances leading to falls. They lasted for several 
hours. Symptoms were intensified by exertion, par-
ticularly during walking (limpness distance was three 
hundred meters). Moreover, the mother observed par-
oxysmal incidents during awaking and falling asleep 
which seemed to be limbs and facial muscles myoclonic 
jerks. A further attack, described as headache, writing 
disturbances, abrupt body stiffness, consciousness dis-
turbances, tightened eyes followed by head and trunk 
dropping on a desk was observed. At the age of 20 trem-
or of upper limbs leading to spill of drinks appeared. 
Furthermore, incidents of hypoglycemia and associ-
ated symptoms were diagnosed. We summarized the 
clinical symptoms during the course of the disease in 
Table 1. During the course of the disease the incidents 
occurred with frequency of one per two years.
Antiepileptic treatment was modified using lamo-
trigine (LTG), VPA, carbamazepine (CBZ), levetiracet-
am (LEV) in different combinations and doses. In the 
course of the disease, arterial hypertension was diag-
nosed additionally.
GLUT 1 deficiency syndrome – diagnosis and treatment
Table 1. Clinical symptoms during the course of disease
Age Symptoms and signs
Infancy “Uncontrolled” eyes (nystagmus)
Head and limbs movement
Trunk twisting
“Stiffness”
Fatigability of lower limbs




The attacks resulted from even little effort
Tension of muscles decreased in limbs
The psychomotor development delayed
Delayed walking, at the age of 2,5 yrs 
Delayed speech, at the age of 3 yrs
The first generalized epileptic seizure at the age of 4 yrs
The second and the last epileptic seizure at the age of 6 yrs
Chlidhood Sudden involuntary movements with collapses
Optic-motor coordination disturbances
Adolescence Paroxysmal speech difficulties (“aphasia”) with pyramidal 
symptoms in right limbs and involuntary movements of lower 
limbs
Gait disturbances lasting for several hours leading to falls, 
escalated by exertion





Tightened eyes followed by head and trunk dropping on a desk
Incidents of hypoglycemia connected with symptoms
Adulthood Tremor of upper limbs 
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Many diagnostic tests were performed so as to iden-
tify the cause of symptoms: MRI scans, EMG with my-
asthenic and tetany tests, RTG of the hips, vertebral col-
umn and feet did not reveal any abnormalities. The EEG 
at the beginning was normal. However, subsequent re-
cordings revealed sharp waves in temporal lobes, some-
times generalized. In one EEG recording general 3 Hz 
delta waves and spike – slow wave complexes with high 
amplitude, activated by hyperventilation.
Because of a suspicion that the patient suffered from 
a metabolic disease, various diagnostic tests were un-
dertaken. However normal blood levels of creatine ki-
nase, cortisol, TSH activity and cyanocobalamin, and 
folic acid were noted. Plasma amino acid levels, organic 
acid profile, acylocarnithynes and transferine isoforms 
pattern were also normal.
However concentrations of free carnitine in urine 
(20 µmol/g [N: 25–330]) and in serum were decreased 
to 27 µmol/l [N: 35–70], whereas lactic acid concentra-
tions in a blood were a little bit elevated (20.66 mg/dl 
[N: 4.5–19.8]), gasometry parameters and alpha glucosi-
dases were normal. Mitochondrial myopathy, encepha-
lopathy, lactic acidosis, stroke-like episodes (MELAS), 
myoclonic epilepsy with ragged red fibers (MERFF), 
neuropathy, ataxia, and retinitis pigmentosa (NARP) 
and Leigh’s syndrome were excluded in genetic tests as 
well as in histopathologic cutaneous-muscular biopsy 
examination. Test of breath chain enzymes activity re-
vealed slightly reduced or normal activity for most en-
zymes except for citrate synthase, which was substan-
tially elevated (354.2 nmol/min/m [N: 96.5-150.1]). Tet-
any and intellectual disability were diagnosed.
RESULTS
The patient was admitted to our neurological depart-
ment when she was twenty years old to investigate 
the reason of “drug resistant epilepsy”. She was treat-
ed with LEV 2000 mg/24h and VPA 1200 mg/24h at 
time of admission.
During the hospitalization, there were no epilep-
tic seizures recorded, but the involuntary movements 
of lower limbs resembling dystonic postures were fre-
quently observed (Fig. 1). EEG revealed only diffuse, 
single slow waves, without sharp waves or spikes. EMG 
composed of conductivity, muscle and myasthenic tests 
was normal. Lumbar puncture was performed and re-
vealed normal t cytosis (4/3) and protein concentra-
tion (30.5 mg/dl) with decreased level of glucose in cer-
ebrospinal fluid (30 mg/dl). The patient was referred 
for genetic tests and genetic consultation with a sus-
picion of GLUT-1 deficiency syndrome. Genetic eval-
uation apart from small head circumference (< 3 c) in 
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Figure 1. Dystonic postures of upper and lower limbs during involuntary movements.
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comparison to height (25 c) did not revealed specific 
dysmorphic features.
Treatment was modified by adding levodopa with 
benserazyd with no clinical improvement. LEV dis-
continuation and reduction of VPA to 900 mg a day 
resulted in elongation of limpness distance from 300 
to 600 meters.
The sequence analysis of the SLC2A1 gene re-
vealed the presence of substitution c.997C > T in ex-
on 8 of one allele leading to missense mutation of pro-
tein p.Arg333Trp (patients genotype c.[997C > T];[=]; 
p.[(Arg333Trp)];[=]. The identified mutation is respon-
sible for GLUT1-DS1 syndrome.
The patient was informed about the ketogenic diet 
as the treatment of choice in this case, but she did not 
accept the recommendation. Subsequently, acetaloza-
mide was prescribed and during the first three months 
of therapy a notable clinical improvement was observed, 
with less frequent involuntary movements, further 
limping distance elongation and self-reliance improve-
ment. Afterwards, another dystonic status, resistant to 
standard therapy and lasting approximately eight hours 
occurred. The patient was hospitalized.
Finally, the patient and her mother accepted to the 
ketogenic diet therapy. Since that time involuntary 
movements stopped for several months. After that time 
the involuntary movements appeared again. The ther-
apy was finally ineffective.
DISCUSSION
The diagnostic criteria for GLUT1-DS include: epilep-
tic seizures, developmental delay, complex movement 
disorder, and fasting EEG changes (Klepper, Leiendeck-
er, 2007). However, some case reports, without classi-
cal course of the disease, have been reported. It was 
for this reason that broadening of GLUT1-DS pheno-
type spectrum to patients with ataxia and mental re-
tardation but without seizures, individuals with dysto-
nia and choreoathetosis, as well as rare cases with ab-
sence seizures and no movement disabilities, occurred. 
Other reported paroxysmal findings include intermit-
tent ataxia, confusion, lethargy, sleep disturbance, and 
headache. Varying degrees of cognitive impairment 
can occur, ranging from learning disabilities to severe 
mental retardation (Pons et al., 2010). In all these cas-
es symptoms exaggerate after exertion. Hypoglycor-
rhachia (CSF glucose less than 40 mg/dl) and low CSF 
lactate are essentially diagnostic for the disorder. Labo-
ratory criteria include also, reduced erythrocyte glucose 
uptake and/or decreased GLUT1 immunoreactivity in 
erythrocyte membranes. Thus the lumbar puncture 
and CSF examination should be the obligatory test in 
all drug resistant patients with epileptic seizures or any 
other paroxysmal incidents. Hypoglycorrhachia should 
be followed by genetic tests to exclude the GLUT1 mu-
tations. Detection of the heterozygous mutations in the 
SLC2A1 gene confirms this diagnosis. In our patient the 
missense mutation p.Arg333Trp, which is responsible 
for GLUT1-DS1 syndrome was identified.
Because of wide variety of symptoms, the exact di-
agnosis is often difficult and delayed. Epileptic seizures, 
being the most common clinical problems, cause the 
decision about introduction and later following mod-
ifications of doses, usually unsuccessfully. It means 
that the proposed treatment maybe wrongly provided 
for years, making the disease pseudo “drug resistant” 
(Pong et al., 2012). Our patient suffered from paroxys-
mal, involuntary movements provoked by stress or ex-
ertion without consciousness disturbances, and she was 
treated as a patient with myoclonic epilepsy using many 
antiepileptic drugs without improvement.
The ketogenic diet is the treatment of choice in the 
GLUT 1 deficiency syndrome, as it provides an alter-
native source of energy to the brain (Klepper, Leien-
decker, 2007). It has been reported that the ketogen-
ic diet effectively controlled seizures and other motor 
symptoms of GLUT1 deficiency, but was less effective 
on cognitive symptoms (Wang et al., 2005). There are 
some case reports describing good clinical response to 
ethosuximide for seizure treatment and to acetazola-
mid for paroxysmal dyskinesia therapy (Anheim et al., 
2011; Gramer et al., 2012). Unfortunately, the ketogenic 
diet is unacceptable for many people, especially, when 
they start to use it in adulthood. Despite the efficacy, 
ketogenic diets deliver only ketone acids to the brain. 
Therefore, it does not resolve the problem with glucose 
supply. Ketogenic diet therapy does not prevent or re-
verse all of the symptoms associated with GLUT1-DS 
and there is a need to develop alternative, more effec-
tive, therapies in the field. It seems reasonable to search 
for another way to supply the brain with glucose.
CONCLUSIONS
One of the possible ways of treatment seems to be glu-
cose intrathecal injection although there have been no 
publications to-date about this therapeutic approach. 
As this kind of therapy is associated with possible side 
effect and complications, it could probably be consid-
GLUT 1 deficiency syndrome – diagnosis and treatment
54 Piotr Bogucki et al.
ered in cases of adult patients who did not respond well 
to other potential drugs and also in patients who did 
not choose to follow the ketogenic diet. It can be con-
sidered in acute clinical states, for instance, dystonic 
states. Further preclinical and clinical trials are needed.
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